|Table of Contents|

Research progress on the relationship between systemic immune-inflammation index and prognosis of ovarian cancer,endometrial cancer and cervical cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 24
Page:
4623-4626
Research Field:
Publishing date:

Info

Title:
Research progress on the relationship between systemic immune-inflammation index and prognosis of ovarian cancer,endometrial cancer and cervical cancer
Author(s):
ZHANG Zexue; CHEN Xiuwei
Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150000,China.
Keywords:
SII; cervical cancer; endometrial cancer; ovarian cancer; prognosis
PACS:
R737.3
DOI:
10.3969/j.issn.1672-4992.2023.24.027
Abstract:
The incidence of three major gynecologic malignant tumors is still high,and it also threatens the health of women seriously.With the improvement of diagnosis and treatment,the early detection rate and the extension of targeted maintenance therapy after operation,the prognosis of gynecologic malignant tumor has been greatly improved.However,the prognosis of patients with early relapse,drug resistance and metastasis is still poor.Therefore,early identification of poor prognosis of cancer patients,developing personalized prevention and treatment strategies is a key issue.Systemic immune-inflammation index (SII) is a comprehensive inflammatory index based on platelet,neutrophil and lymphocyte counts.It can reflect the balance between immune state and inflammation more comprehensively,and the high levels of SII in malignant tumors usually predict adverse outcomes.This article will review the association of SII with the prognosis of patients with ovarian cancer,endometrial cancer,and cervical cancer.

References:

[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2] GE MY,LIU ZP,PAN Y,et al.Assessment of the prognostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in perihilar cholangiocarcinoma patients following curative resection:A multicenter study of 333 patients［J］.Front Oncol,2022,12:1104810.
[3] ANDERSEN BL,MYERS J,BLEVINS T,et al.Depression in association with neutrophil-to-lymphocyte,platelet-to-lymphocyte,and advanced lung cancer inflammation index biomarkers predicting lung cancer survival［J］.PLoS One,2023,18(2):e0282206.
[4] HU B,YANG XR,XU Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma［J］.Clin Cancer Res,2014,20(23):6212-6222.
[5] WANG D,HU X,XIAO L,et al.Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC［J］.J Gastrointest Surg,2021,25(2):421-427.
[6] DEMIRCAN NC,ATCI MM,DEMIR M,et al.Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy［J］.Asia Pac J Clin Oncol,2023,19(1):104-112.
[7] MURTHY P,ZENATI MS,AL ABBAS AI,et al.Prognostic value of the systemic immune-inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer［J］.Ann Surg Oncol,2020,27(3):898-906.
[8] YANG J,DENG M,BI M,et al.Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer［J］.Future Sci OA,2022,8(5):Fso798.
[9] YAMASHITA S,IWAHASHI Y,MIYAI H,et al.Usefulness of preoperative high systemic immune-inflammation index as a prognostic biomarker in patients who undergo radical cystectomy for bladder cancer:multicenter analysis［J］.Diagnostics (Basel),2021,11(12):2194.
[10] 林琳,李娜,吴丽娜,等.外周血NLR、MLR、SII在甲状腺髓样癌中的应用价值［J］.现代肿瘤医学，2022，30（10）:1753-1757. LIN Lin,LI Na,WU Lina,et al.Exploration of the application value of peripheral blood NLR,MLR and SII in medullary thyroid carcinoma［J］.Modern Oncology,2022，30（10）:1753-1757.
[11] AKSOY E,KARAKURT Z,GUNGOR S,et al.Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes［J］.Int J Chron Obstruct Pulmon Dis,2018,13:2721-2730.
[12] MISHALIAN I,BAYUH R,LEVY L,et al.Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression［J］.Cancer Immunol Immunother,2013,62(11):1745-1756.
[13] ABU-SHAWER O,ABU-SHAWER M,HIRMAS N,et al.Hematologic markers of distant metastases and poor prognosis in gynecological cancers［J］.BMC Cancer,2019,19(1):141.
[14] ZHOU SL,ZHOU ZJ,HU ZQ,et al.Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib［J］.Gastroenterology,2016,150(7):1646-1658.
[15] GRIVENNIKOV SI,GRETEN FR,KARIN M.Immunity,inflammation,and cancer［J］.Cell,2010,140(6):883-899.
[16] FRANCO AT,CORKEN A,WARE J.Platelets at the interface of thrombosis,inflammation,and cancer［J］.Blood,2015,126(5):582-588.
[17] SAHA B,KHATUN N,AZIM N,et al.Platelet count as a prognostic factor in stage IV non-small cell lung cancer［J］.Mymensingh Med J,2022,31(4):937-946.
[18] HUANG H,LI L,LUO W,et al.Lymphocyte percentage as a valuable predictor of prognosis in lung cancer［J］.J Cell Mol Med,2022,26(7):1918-1931.
[19] SAWA A,BANDO H,KAMOHARA R,et al.Absolute lymphocyte count as an independent prognostic factor in metastatic breast cancer:a retrospective study［J］.Oncology,2022,100(11):591-601.
[20] LEE YJ,PARK YS,LEE HW,et al.Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer［J］.Sci Rep,2022,12(1):626.
[21] SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2022［J］.CA Cancer J Clin,2022,72(1):7-33.
[22] MATSUBARA S,MABUCHI S,TAKEDA Y,et al.Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer［J］.PLoS One,2021,16(5):e0248871.
[23] HOLUB K,BUSATO F,GOUY S,et al.Analysis of systemic inflammatory factors and survival outcomes in endometrial cancer patients staged I-III FIGO and treated with postoperative external radiotherapy［J］.J Clin Med,2020,9(5):1441.
[24] HUANG Y,CHEN Y,ZHU Y,et al.Postoperative systemic immune-inflammation index (SII):A superior prognostic factor of endometrial cancer［J］.Front Surg,2021,8:704235.
[25] NJOKU K,RAMCHANDER NC,WAN YL,et al.Pre-treatment inflammatory parameters predict survival from endometrial cancer:A prospective database analysis［J］.Gynecol Oncol,2022,164(1):146-153.
[26] SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2018［J］.CA Cancer J Clin,2018,68(1):7-30.
[27] CANNISTRA SA.Cancer of the ovary［J］.N Engl J Med,2004,351(24):2519-2529.
[28] NIE D,GONG H,MAO X,et al.Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer:A retrospective study［J］.Gynecol Oncol,2019,152(2):259-264.
[29] BIZZARRI N,D' INDINOSANTE M,MARCHETTI C,et al.The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer［J］.Int J Clin Oncol,2023,28(2):314-320.
[30] JI Y,WANG H.Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers:a meta-analysis［J］.World J Surg Oncol,2020,18(1):197.
[31] FAROLFI A,PETRONE M,SCARPI E,et al.Inflammatory indexes as prognostic and predictive factors in ovarian cancer treated with chemotherapy alone or together with bevacizumab.A multicenter,retrospective analysis by the MITO group (MITO 24)［J］.Target Oncol,2018,13(4):469-479.
[32] DOGHISH AS,ALI MA,ELYAN SS,et al.miRNAs role in cervical cancer pathogenesis and targeted therapy:Signaling pathways interplay［J］.Pathol Res Pract,2023,244:154386.
[33] HOLUB K,BIETE A.Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients［J］.Clin Transl Oncol,2019,21(7):836-844.
[34] HUANG H,LIU Q,ZHU L,et al.Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer［J］.Sci Rep,2019,9(1):3284.
[35] LIU P,JIANG Y,ZHENG X,et al.Pretreatment systemic immune-inflammation index can predict response to neoadjuvant chemotherapy in cervical cancer at stages IB2-IIB［J］.Pathol Oncol Res,2022,28:1610294.

Memo

Memo:
National Natural Science Foundation of China(No.82073239）；国家自然科学基金（编号：82073239）
Last Update: 1900-01-01